Myciclib 125mg Capsule

About

Myciclib 125mg Capsule is an oral, highly selective cyclin-dependent kinase (CDK) 4/6 inhibitor, primarily indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This targeted therapy works by blocking the activity of CDK4 and CDK6, key enzymes that regulate cell cycle progression from the G1 phase to the S phase. In many cancers, these CDKs are overactive, leading to uncontrolled cell proliferation. By inhibiting CDK4/6, Myciclib effectively arrests the cell cycle, preventing cancer cells from dividing and growing, thereby slowing tumor progression. It is typically used in combination with endocrine therapy, such as an aromatase inhibitor or fulvestrant, to enhance therapeutic efficacy and improve progression-free survival in eligible patients, offering a significant advancement in breast cancer management.

Uses

• HR+, HER2- advanced or metastatic breast cancer
• Used in combination with an aromatase inhibitor
• Used in combination with fulvestrant
• First-line or subsequent-line therapy

Directions For Use

Take orally with or without food, as directed by your physician. Swallow the capsule whole; do not chew, crush, or open.

Benefits

• Significantly improves progression-free survival.
• Effective in HR+, HER2- metastatic breast cancer.
• Can be used in combination with endocrine therapy.
• Oral administration offers convenience.
• Well-established efficacy in clinical trials.
• Offers a targeted approach to cancer treatment.

Side Effects

• Neutropenia (low white blood cell count)
• Leukopenia (low white blood cell count)
• Fatigue
• Nausea
• Diarrhea
• Stomatitis (mouth sores)
• Hair thinning (alopecia)
• Anemia
• Thrombocytopenia (low platelet count)
• Infections
• Elevated liver enzymes
• Interstitial lung disease (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver toxicity or gastrointestinal side effects.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
• Breastfeeding - Not recommended during breastfeeding as the drug may pass into breast milk and harm the infant. Discontinue breastfeeding.
• Liver - Use with caution in patients with pre-existing liver impairment; dose adjustments may be necessary based on liver function tests.
• Kidney - No specific dose adjustment typically required for mild to moderate renal impairment, but monitor renal function.
• Lung - Monitor for signs and symptoms of interstitial lung disease/pneumonitis; discontinue if confirmed and manage appropriately.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.